NVAX receives $1.6 billion from Trump’s Operation Warp Speed, causing Novavax to cross $100 – should you invest?

Novavax (NASDAQ: NVAX) inched closer to the COVID-19 vaccine finish line after receiving $1.6 billion in government funding today. The bulls are now rally in large numbers behind the COVID-19 biotech. Especially in light of today’s announcement. However, many investors wonder how long it will be until the NVAX bulls have to rest? Because if …

INO falls 18% on positive phase I COVID-19 trials – where to next for investors?

Inovio Pharmaceuticals (NASDAQ: INO), last week’s COVID-19 spectacle has now capitulated investors into no mans land after falling after positive Phase I data. It seems strange right, investors were backing INO with the expectation of positive phase I trials. INO fulfilled the expectation yet the bears decided to take the biotech to the woodshed. The …

Vaxart rises 300% after its COVID-19 vaccine joins Trump’s Operation Warp Speed – is now the time to invest?

Vaxart Incorporated (NASDAQ: VXRT), wrenched the spotlight off COVID-19 frontrunners after its oral vaccine received funding from “Operation Warp Speed,” Trump’s accelerated vaccine program. The funding is causing investors to empty their wallets into the stock. The stock did skyrocket to the moon initially. However, now VXRT is following a downward spiral. Investors just becoming …

ESKO skyrockets 170% after FDA approves its brain injury device – is Esko Bionics worth the investment?

Esko bionics (NASDAQ: ESKO) is causing the eyes of investors light up with money symbols after the FDA gave the green light yesterday. While volatility is high, the future is showing signs of upward growth. However, the bears could ignite a sell-off at any point. Making many investors wonder, is Esko Bionics a good investment? …

SRNE surges 20% off COVID-19 lawsuit – has news been leaked?

Sorrento Therapeutics’ (NASDAQ: SRNE) saying they have a COVID-19 treatment that offers a 100% protection, before conducting trials, was an incredibly bold statement. SRNE’s optimistic announcement not only lit the investment world alight but also pushed them into the legal spotlight. It is the possible lawsuit charges that caused the bears to multiply. However, SRNE …

INO’s COVID-19 vaccine receives $71 million in government funding – how high can the INO stock go?

The COVID-19 vaccine market was fading as economies began to recover. However, the insurgence of new coronavirus cases and deaths is causing investors to gravitate towards COVID-19 vaccine frontrunners Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX), and Inovio Pharmaceuticals (NASDAQ: INO). It makes logical sense that investors rally behind the vaccine companies. Especially as they have …

BREAKING: Glenmark’s COVID-19 drug gets market approval – causing an enormous rally in India today.

Glenmark Pharmaceuticals (XNSE: GLENMARK) COVID-19 drug, FabiFlu, is acting as a magnet to the eyes and wallets of investors. Considering India has 426,910 coronavirus cases and counting, it makes sense that many eyeballs are watching the Mumbai based biotech. Indian COVID-19 cases are forecasted to grow before they flatten. Thus, many investors are scratching their …

Enochian Biosciences Skyrockets 240% pre-market on potential HIV cure

Enochian Biosciences (NASDAQ:ENOB) stock price has set for the stars this morning – with pre markets predicting the stock to open 240% higher. The significant increase has come off the back of a press release confirming an FDA meeting which successfully “aligned” with Enochian’s strategy for a HIV cure. This news although a first of …

Gilead produces mixed COVID-19 trial results – investors now look to Mesoblast.

Biotechs universally share one mission. The industry aims to prevent or cure diseases to sustain a higher life expectancy. If a biotech successfully achieves its mission, humankind, the patients suffering, and investors all experience euphoria. However, if a biotech fails to develop a viable drug then the nightmarish scenario of people suffering continues. It seems …

ADAP soars 150% on positive Phase 1 cancer trials – is a sell-off inevitable?

Why did the ADAP surge this week? Adaptimmune Therapeutics PLC (Nasdaq: ADAP) skyrocketed 128% on Friday. Investors rallied behind ADAP because of their positive phase 1 cancer trial. ADAP’s synovial sarcoma cancer candidate (ADP-A2M4) reported a 50% response rate in patients suffering from lung, head, and neck cancers. The phase 1 trial confirmed the safeness, …

SNOA explodes 150% after the ARTG approves their COVID-19 sanitiser

Biotechs are having a field day on Wall Street as every day, a new 100% gain is coming across our desks. The unrealistic gains highlight just how unique the current bear market is. Mainly because a worldwide pandemic is not the typical root cause of financial crises. From the oil recession in 1973 to extreme …

ABIO skyrockets 225% today on COVID-19 treatment – have all the gains been made?

An important lesson to understand in investing is that buyers invest in what they believe to be true even if it is false. Biotechs popping up every second and developing a possible COVID-19 treatment is a perfect example. Many investors buy into the biotech on the belief that the company could develop a viable treatment. …

Mersana Therapeutics reports positive cancer drug results – causing uncontrolled buying.

A cure for cancer is the most desirable statement for scientists and investors alike. However, optimism is often met with disappointment as the task of curing cancer is no easy feat. Despite the difficulty, the scientific world continues to develop drug after drug in an attempt to eradicate the horrific group of diseases. Despite a …